Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program - Adenis, A; Andre, T; de la Fouchardiere, C; Paule, B; Burtin, P; Tougeron, D (BMC Cancer, 2016)